JP2013503148A5 - - Google Patents

Download PDF

Info

Publication number
JP2013503148A5
JP2013503148A5 JP2012526141A JP2012526141A JP2013503148A5 JP 2013503148 A5 JP2013503148 A5 JP 2013503148A5 JP 2012526141 A JP2012526141 A JP 2012526141A JP 2012526141 A JP2012526141 A JP 2012526141A JP 2013503148 A5 JP2013503148 A5 JP 2013503148A5
Authority
JP
Japan
Prior art keywords
composition
oligonucleotide
polymer
aluminum salt
immunogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2012526141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013503148A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2010/002259 external-priority patent/WO2011024071A1/en
Publication of JP2013503148A publication Critical patent/JP2013503148A/ja
Publication of JP2013503148A5 publication Critical patent/JP2013503148A5/ja
Ceased legal-status Critical Current

Links

JP2012526141A 2009-08-27 2010-08-27 アルミニウム、オリゴヌクレオチドおよびポリカチオンを含むアジュバント Ceased JP2013503148A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23759509P 2009-08-27 2009-08-27
US61/237,595 2009-08-27
PCT/IB2010/002259 WO2011024071A1 (en) 2009-08-27 2010-08-27 Adjuvant comprising aluminium, oligonucleotide and polycation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015236813A Division JP2016034980A (ja) 2009-08-27 2015-12-03 アルミニウム、オリゴヌクレオチドおよびポリカチオンを含むアジュバント

Publications (2)

Publication Number Publication Date
JP2013503148A JP2013503148A (ja) 2013-01-31
JP2013503148A5 true JP2013503148A5 (cg-RX-API-DMAC7.html) 2013-07-25

Family

ID=43428549

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012526141A Ceased JP2013503148A (ja) 2009-08-27 2010-08-27 アルミニウム、オリゴヌクレオチドおよびポリカチオンを含むアジュバント
JP2015236813A Pending JP2016034980A (ja) 2009-08-27 2015-12-03 アルミニウム、オリゴヌクレオチドおよびポリカチオンを含むアジュバント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015236813A Pending JP2016034980A (ja) 2009-08-27 2015-12-03 アルミニウム、オリゴヌクレオチドおよびポリカチオンを含むアジュバント

Country Status (9)

Country Link
US (1) US8858958B2 (cg-RX-API-DMAC7.html)
EP (1) EP2470205A1 (cg-RX-API-DMAC7.html)
JP (2) JP2013503148A (cg-RX-API-DMAC7.html)
CN (1) CN102740882A (cg-RX-API-DMAC7.html)
AU (1) AU2010288239B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012004276A2 (cg-RX-API-DMAC7.html)
CA (1) CA2772103A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ598459A (cg-RX-API-DMAC7.html)
WO (1) WO2011024071A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010032138A2 (en) * 2008-09-18 2010-03-25 Novartis Ag Vaccine adjuvant combinations
CA2875391A1 (en) 2012-07-27 2014-01-30 Institut National De La Sante Et De La Recherche Medicale Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
SG11201700839SA (en) * 2014-08-04 2017-03-30 Oncotherapy Science Inc Cdca1-derived peptide and vaccine containing same
CN112138155B (zh) * 2019-06-28 2022-04-12 怡道生物科技(苏州)有限公司 一种复合佐剂系统及制备该佐剂的方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
DE69334197T2 (de) 1992-03-02 2008-12-11 Novartis Vaccines And Diagnostics S.R.L. Helicobacter pylori Cytotoxin verwendbar in Impfstoffe und Diagnostik
NL9201716A (nl) 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
AU695769B2 (en) 1994-07-01 1998-08-20 Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin, The Helicobacter proteins and vaccines
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
JPH11513372A (ja) * 1995-09-22 1999-11-16 コノート ラボラトリーズ リミテッド パラインフルエンザウイルスの糖タンパクおよびワクチン
DK0909323T3 (da) 1996-01-04 2007-05-21 Novartis Vaccines & Diagnostic Helicobacter pylori-bakterioferritin
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
DE69841122D1 (de) 1997-03-10 2009-10-15 Coley Pharm Gmbh Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
WO1998053851A1 (en) 1997-05-28 1998-12-03 University Of Iowa Research Foundation Laft mutants of pathogenic gram-negative bacteria
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
WO1999010497A1 (en) 1997-08-21 1999-03-04 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Novel mutants of gram negative mucosal bacteria and application thereof in vaccines
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
US6645503B1 (en) 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
EP2261357A3 (en) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
WO2000023595A1 (en) 1998-10-22 2000-04-27 The University Of Montana Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
JP3595264B2 (ja) 1998-11-03 2004-12-02 デ・スタート・デル・ネーデルランデン・ベルテゲンボールディクト・ドール・デ・ミニステル・バン・ベルジーン・ボルクスゲツォントヘイト・エン・クルトゥール 遺伝的に修飾されたグラム陰性細菌由来の低毒性ｌｐｓ
ES2522667T3 (es) 1999-04-30 2014-11-17 Novartis Vaccines And Diagnostics S.R.L. Antígenos Neisseriales conservados
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
RU2002117308A (ru) 1999-11-29 2004-03-10 Чирон Спа (It) 85 кДа АНТИГЕН NEISSERIA
US8273360B2 (en) 2000-01-17 2012-09-25 Novartis Ag Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
MXPA02007184A (es) 2000-01-25 2004-02-26 Univ Queensland Proteinas que comprenden regiones conservadas de antigenos de superficie nhha de neisseria meningitidis.
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
BRPI0111639B8 (pt) 2000-06-08 2021-05-25 Intercell Ag uso de uma molécula de ácido oligodeoxinucléico imunoestimulatório e composição farmacêutica.
CA2414884A1 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
BRPI0112928B1 (pt) 2000-07-27 2017-08-29 Children's Hospital & Research Center At Oakland A composition comprising preparations comprising outer membrane vesicles (OMV), microvesicles (MV) or both MVO and MV
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
EP1409013B1 (en) 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2003049762A2 (en) 2001-12-12 2003-06-19 Chiron Srl. Immunisation against chlamydia trachomatis
ES2320334T3 (es) 2002-02-22 2009-05-21 National Research Council Of Canada Uso de analogos de acidos grasos para el tratamiento y/o prevencion de enfermedades proliferativas de la piel.
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
DK2255826T3 (en) 2002-08-02 2016-06-20 Glaxosmithkline Biologicals Sa Neisserial vaccine compositions comprising a combination of antigens.
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
EP2353608B1 (en) 2002-10-11 2019-12-18 Novartis Vaccines and Diagnostics S.r.l. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
JP2006521321A (ja) * 2003-03-24 2006-09-21 インターツェル・アクチェンゲゼルシャフト 免疫応答を促進するためのミョウバンおよびＴｈ１免疫応答誘起アジュバントの使用
DE602004029657D1 (de) * 2003-03-24 2010-12-02 Intercell Ag Verbesserte impfstoffe
CN1812809A (zh) 2003-06-26 2006-08-02 希龙公司 用于沙眼衣原体的免疫原性组合物
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
CA2557353A1 (en) 2004-03-02 2005-09-15 Chiron Corporation Immunogenic compositions for chlamydia pneunomiae
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
ES2616294T3 (es) 2005-01-27 2017-06-12 Children's Hospital & Research Center At Oakland Vacunas de vesículas basadas en GNA1870 para protección de amplio espectro contra enfermedades provocadas por Neisseria meningitidis
NZ599345A (en) 2005-02-18 2013-07-26 Novartis Vaccines & Diagnostic Immunogens from uropathogenic Escherichia Coli
SG160329A1 (en) * 2005-02-18 2010-04-29 Novartis Vaccines & Diagnostic Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
CA2608278A1 (en) 2005-05-12 2006-12-28 Guido Grandi Immunogenic compositions for chlamydia trachomatis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US8481057B2 (en) 2005-12-22 2013-07-09 Novartis Vaccines & Diagnostics Srl Chlamydial antigens
CA2633789A1 (en) * 2005-12-23 2007-06-28 Glaxosmithkline Biologicals Sa Conjugate vaccines
ES2390291T3 (es) 2006-06-12 2012-11-08 Glaxosmithkline Biologicals S.A. Vacunas LOS L3V
CA2659552A1 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
CA2706617A1 (en) 2007-11-26 2009-06-25 Novartis Ag Adjuvanted glucans
CN101971030A (zh) 2007-12-24 2011-02-09 诺华有限公司 流感吸附疫苗的试验
ES2532946T3 (es) 2008-02-21 2015-04-06 Novartis Ag Polipéptidos PUfH meningocócicos
ITMI20081249A1 (it) 2008-07-09 2010-01-09 Novartis Vaccines & Diagnostic Immunogeni di escherichia coli con solubilità migliorata.
WO2010032138A2 (en) 2008-09-18 2010-03-25 Novartis Ag Vaccine adjuvant combinations

Similar Documents

Publication Publication Date Title
JP6101330B2 (ja) アジュバント添加した髄膜炎菌ｈ因子結合タンパク質
CN110520154B (zh) 多价肺炎链球菌疫苗组合物
JP5344558B2 (ja) カチオン性ナノゲルを用いる粘膜ワクチン
WO2017143024A2 (en) Pathogen vaccines and methods of producing and using the same
JP2014525429A5 (cg-RX-API-DMAC7.html)
JP2013522287A5 (cg-RX-API-DMAC7.html)
CN104093418A (zh) 金黄色葡萄球菌抗原的含佐剂制剂
JP2013501071A5 (cg-RX-API-DMAC7.html)
JP2010508276A5 (cg-RX-API-DMAC7.html)
US20250152700A1 (en) Aluminum nanocrystal delivery system, and self-assembled particle adjuvant vaccine based on binding of aluminum nanocrystal delivery system and vaccine antigen molecule
JP2013503148A5 (cg-RX-API-DMAC7.html)
US20220331424A1 (en) Composite adjuvant system and method for preparing adjuvant
WO2023131356A2 (zh) 四氧化三锰颗粒在制备疫苗佐剂中的应用
CN102716474B (zh) 蛋白Rh054_01780在抗黑龙江立克次体的免疫保护中的应用
JP2016034980A (ja) アルミニウム、オリゴヌクレオチドおよびポリカチオンを含むアジュバント
Liao et al. Carbopol dispersed PAA-modified UIO-66 with high colloidal stability as a combination nano-adjuvant boosts immune response and protection against pseudorabies virus in mice and pigs
EP2221050A1 (en) Use of microparticles for vaccines and the release of biologically active molecules
US20140248310A1 (en) Cationic metal oxides for use as vaccine adjuvants
Rosales-Mendoza et al. Silica-based mucosal nanovaccines
JP4711964B2 (ja) ワクチンのアジュバントとしてリン酸鉄を含むワクチン組成物
Ohta Cholesteryl Pullulan Nanoparticles-Encapsulated TNF-a: An Effective Mucosal Vaccine Adjuvant Against
Herbert et al. COORDINATION POLYMER MATRIXES INTENSIFY IMMUNITY AGAINST BLADDER INFECTION
HK40119504A (en) Aluminum nanocrystal delivery system, and self-assembled particle adjuvant vaccine based on binding of aluminum nanocrystal delivery system and vaccine antigen molecule
HK40011275B (zh) 多价肺炎链球菌疫苗组合物
AU2013202541A1 (en) Adjuvant comprising aluminium, oligonucleotide and polycation